Galectin prepares for secondary offering

Galectin Therapeutics (GALT) files an S-3 for a $100M secondary offering of common stock plus 500,000 shares of common registered for sale by Richard Uihlein.

The offering includes a sales agreement with MLV & Co. for up to $30M of potential time-to-time future sales.

This was corrected on 03/24/2014 at 02:42 PM.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs